Decrease of MLK4 prevents hepatocellular carcinoma (HCC) through reducing metastasis and inducing apoptosis regulated...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
• Understanding the molecular drivers of hepatocarcinogenesis is crucial for developing effective treatments.
• The role of Mixed Lineage Kinase 4 (MLK4) in HCC progression is currently unclear.

Purpose of the Study:

• To investigate the role of MLK4 in hepatocellular carcinoma (HCC) progression.
• To elucidate the molecular mechanisms by which MLK4 influences HCC cell behavior.
• To evaluate MLK4 as a potential therapeutic target for HCC.

Main Methods:

• Analysis of MLK4 expression in HCC tumor samples.
• In vitro studies involving MLK4 knockdown in HCC cell lines.
• Assessment of cell proliferation, metastasis, apoptosis, and reactive oxygen species (ROS) production.
• In vivo studies using xenograft models to evaluate tumor growth and metastasis.
• Investigation of signaling pathways including MAPKs (p38, JNK, ERK1/2).

Main Results:

• MLK4 was found to be overexpressed in HCC tumors and associated with poorer survival.
• MLK4 knockdown suppressed HCC cell proliferation and metastasis, partly by reducing MMP-13, MMP2, EZH2, and Vimentin.
• MLK4 knockdown induced apoptosis by altering Bcl-2, cleaved PARP, Caspase-7, and Caspase-3 levels.
• MLK4 knockdown increased ROS production and activated MAPKs signaling, which were critical for MLK4 knockdown-induced apoptosis and suppressed metastasis.
• In vivo, MLK4 knockdown inhibited tumor growth and reduced lung metastasis in xenograft models.

Conclusions:

• MLK4 plays a significant role in promoting hepatocellular carcinoma (HCC) progression.
• MLK4 influences HCC via modulation of proliferation, metastasis, apoptosis, and ROS production.
• Targeting MLK4, potentially through modulation of ROS and MAPK pathways, presents a promising therapeutic strategy for HCC.